ArticleEuropean journal of nuclear medicine and molecular imaging2024
A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05613738 (Safety and Dosimetry of 177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Dosimetry of 177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- PSMA-targeted radioligand therapy with [European journal of nuclear medicine and molecular imaging · 2025Trial
- 177 Lu-PSMA for prostate cancer: progress, challenges and future perspectives.Asian journal of andrology · 2026Review
- The Prognostic Value ofAnnals of nuclear medicine · 2026Article
- A peptide nucleic acid-based pretargeting approach usingEJNMMI research · 2026Article
- Combination therapy strategies in engineeredCell communication and signaling : CCS · 2026Review
- Phase I dose-escalation study of [¹⁷⁷Lu]Lu-LNC1011, a long-circulating dansyl-modified PSMA theranostics, in metastatic castration-resistant prostate cancer.Theranostics · 2026Article
- Tailored Reaction Conditions and Automated Radiolabeling of [International journal of molecular sciences · 2025Article
- Development of [European journal of nuclear medicine and molecular imaging · 2025Article
- Deciphering the Tumor Uptake of Heterobivalent (SSTJournal of medicinal chemistry · 2025Article
- Biodistribution and dosimetry of [European journal of nuclear medicine and molecular imaging · 2025Article
- Enhanced NIR-II Nanoparticle Probe for PSMA-Targeted Molecular Imaging and Prostate Cancer Diagnosis.International journal of nanomedicine · 2025Article
- Design and conduct of theranostic trials in neuro-oncology: Challenges and opportunities.Neuro-oncology · 2024Review
- Comparison of novel PSMA-targeting [European journal of nuclear medicine and molecular imaging · 2024Article
- Metastatic castration-resistant prostate cancer therapy: the quest for the perfect molecule.European journal of nuclear medicine and molecular imaging · 2024Article
- Prostate-specific membrane antigen-targeted surgery in prostate cancer: Accurate identification, real-time diagnosis, and precise resection.Theranostics · 2024Review
- Theranostics - a sure cure for cancer after 100 years?Theranostics · 2024Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
Abstract
purposeThis translational study aimed to determine the maximum tolerated dose (MTD), safety, dosimetry, and therapeutic efficacy of
methodsA total of 13 patients with mCRPC were recruited in this study. A standard 3 + 3 dose escalation protocol was performed. The following dose levels were ultimately evaluated: 1.11, 1.85, and 2.59 GBq/cycle. Patients received [
resultsPatients received fractionated doses of [
conclusionThis phase 1 trial revealed that the MTD of [
trial registrationCLINICALTRIALS: gov/ct2/show/NCT05613738.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.